Browse our anti-B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies

Full name:
anti-B-Cell CLL/lymphoma 9-Like Antibodies (BCL9L)
On are 33 B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies from 11 different suppliers available. Additionally we are shipping B-Cell CLL/lymphoma 9-Like Proteins (3) and B-Cell CLL/lymphoma 9-Like Kits (2) and many more products for this protein. A total of 48 B-Cell CLL/lymphoma 9-Like products are currently listed.
2610202E01Rik, 8030475K17Rik, A330041G23Rik, B9L, BC003321, bcl9-2, BCL9L, DLNB11, Gm130, LGS
list all antibodies Gene Name GeneID UniProt
BCL9L 77578 Q9D219
BCL9L 607 O00512
BCL9L 300673  

Show all species

Show all synonyms

Most Popular Reactivities for anti-B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies

Select your species and application

anti-Mouse (Murine) Antibodies:

anti-Human Antibodies:

anti-Rat (Rattus) Antibodies:

All available anti-B-Cell CLL/lymphoma 9-Like Antibodies

Go to our pre-filtered search.

Top referenced anti-B-Cell CLL/lymphoma 9-Like Antibodies

  1. Human Polyclonal BCL9L Primary Antibody for WB - ABIN1881110 : Miller, Rutherford, Johnson, Fiedler, Bienz: Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. in Journal of molecular biology 2010 (PubMed)
    Show all 5 references for 1881110

  2. Human Polyclonal BCL9L Primary Antibody for EIA, WB - ABIN783409 : Adachi, Jigami, Yasui, Nakano, Ohwada, Omori, Sugano, Ohkawara, Shibuya, Nakamura, Akiyama: Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. in Cancer research 2004 (PubMed)
    Show all 4 references for 783409

More Antibodies against B-Cell CLL/lymphoma 9-Like Interaction Partners

Mouse (Murine) B-Cell CLL/lymphoma 9-Like (BCL9L) interaction partners

  1. Study demonstrates that the Golgi resident protein GM130 (show GOLGA2 Antibodies) activates the spindle assembly factor TPX2 (show DAZL Antibodies) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.

  2. BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells.

  3. Pax6 (show PAX6 Antibodies), the master regulator of eye development, directly activates Bcl9 (show BCL9 Antibodies)/9l transcription.

  4. Data show that the GCM1/syn (show CTNNB1 Antibodies)cytin (show BCL9 Antibodies)-B pathway is significantly downregulated in the placenta of BCL9L-defici (show GCM1 Antibodies)ent mice (show ERVW-1 Antibodies)and that the fusion and differentiation of ST-II cells are blocked.

  5. BCL9-2 promotes early phases of intestinal tumor progression in humans and in transgenic mice. BCL9-2 increases the expression of a subset of canonical Wnt (show WNT2 Antibodies) target genes but also regulates genes that are required for early stages of tumor progression.

  6. These results suggest a critical role of BCL9 (show BCL9 Antibodies)/9-2 in the Wnt (show WNT2 Antibodies)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.

  7. We demonstrated that nuclear B9L expression was closely associated with the high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 (show ERBB2 Antibodies) in breast cancers.

Human B-Cell CLL/lymphoma 9-Like (BCL9L) interaction partners

  1. MEF2D (show MEF2D Antibodies)-BCL9 (show BCL9 Antibodies)-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (show HDAC9 Antibodies).

  2. BCL9L dysfunction contributes to aneuploidy tolerance in both TP53 (show TP53 Antibodies)-WT and mutant cells by reducing basal caspase-2 (show CASP2 Antibodies) levels and preventing cleavage of MDM2 (show MDM2 Antibodies) and BID (show BID Antibodies).

  3. it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC (show XRCC1 Antibodies) oncogenesis.

  4. findings indicate that BCL9 (show BCL9 Antibodies) most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population

  5. BCL9 (show BCL9 Antibodies)/9L-beta-catenin (show CTNNB1 Antibodies) Signaling is Associated With Poor Outcome in Colorectal Cancer

  6. BCL9 (show BCL9 Antibodies) is a molecular driver of DCIS invasive progression.

  7. PCDH10 (show PCDH10 Antibodies) antagonized MM cell proliferation via the downregulation of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies)/BCL-9 (show BCL9 Antibodies) signaling, whereas PCDH10 (show PCDH10 Antibodies) repressed the expression of AKT (show AKT1 Antibodies) to promote the expression of GSK3beta (show GSK3b Antibodies) and then to restrain the activation of beta-catenin (show CTNNB1 Antibodies)

  8. The inhibition of the transcriptional activity of BCL9-2 by WWOX (show WWOX Antibodies) and HDAC3 (show HDAC3 Antibodies) constitutes a new molecular mechanism and provides new insight for a broad range of cancers.

  9. BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells.

  10. By beta-catenin's association with LEF1 (show LEF1 Antibodies) and BCL9-2/B9L.

B-Cell CLL/lymphoma 9-Like (BCL9L) Antigen Profile

Antigen Summary

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

Alternative names and synonyms associated with B-Cell CLL/lymphoma 9-Like (BCL9L)

  • B-cell CLL/lymphoma 9-like (BCL9L) antibody
  • B cell CLL/lymphoma 9 (Bcl9) antibody
  • B cell CLL/lymphoma 9-like (Bcl9l) antibody
  • B-cell CLL/lymphoma 9 (BCL9) antibody
  • B-cell CLL/lymphoma 9-like (Bcl9l) antibody
  • B-cell CLL/lymphoma 9-like (bcl9l) antibody
  • 2610202E01Rik antibody
  • 8030475K17Rik antibody
  • A330041G23Rik antibody
  • B9L antibody
  • BC003321 antibody
  • bcl9-2 antibody
  • BCL9L antibody
  • DLNB11 antibody
  • Gm130 antibody
  • LGS antibody

Protein level used designations for BCL9L

B-cell CLL/lymphoma 9-like , b-cell CLL/lymphoma 9-like protein-like , B-cell CLL/lymphoma 9 protein , B-cell lymphoma 9 protein , bcl-9 , nuclear co-factor of beta-catenin signalling , B-cell CLL/lymphoma 9-like protein , B-cell lymphoma 9-like protein , BCL9-like protein , BCL9-related beta-catenin-binding protein , protein BCL9-2 , protein legless homolog

419785 Gallus gallus
451596 Pan troglodytes
489377 Canis lupus familiaris
539340 Bos taurus
100063146 Equus caballus
100444640 Pongo abelii
100515846 Sus scrofa
77578 Mus musculus
80288 Mus musculus
607 Homo sapiens
100155378 Sus scrofa
283149 Homo sapiens
300673 Rattus norvegicus
449532 Danio rerio
Selected quality suppliers for anti-B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies
Did you look for something else?